PARIS--(BUSINESS WIRE)--Regulatory News: “Our pipeline of products for orphan diseases and rare and severe cancers is a huge reservoir of value” BioAlliance Pharma SA (Euronext Paris –BIO), a company dedicated to specialty and orphan pharma products in oncology and supportive care, today reported a consolidated turnover of €604,000 for the first quarter of 2011. This turnover is constituted for €560,000 of recurring revenues from licensing agreements for Loramyc®.
